OCMS logo
Oxford University Crest

 

Publications by OCMS Members and staff

2000/2001

* indicates OCMS author

  1. A switch in heme axial ligation prepares Paracoccus pantotrophus cytochrome cd(1) for catalysis. Allen JWA, Watmough NJ & Ferguson SJ*, Nature Struct Biol 7(10), 885-888 2000.
  2. Expression and purification of mammalian calreticulin in Pichia pastoris. Andrin C, Corbett E, Johnson S*, Dabrowska M, Campbell ID*, Eggleton P, Opas M & Michalak M, Protein Expression & Purification 20(2), 207-215 2000.
  3. The role of the Src homology 3-Src homology 2 interface in the regulation of Src kinases. Arold ST, Ulmer TS, Mulhern TD*, Werner JM*, Ladbury JE, Campbell ID* & Noble M*, J Biol Chem 276(20), 17199-17205 2001.
  4. Macromolecular assemblies: greater than their parts. Bamford DH, Gilbert RJC*, Grimes JM & Stuart DI*, Current Opinion in Structural Biology 11(1), 107-113 2001.
  5. Cis- and trans-3-Azido-oxetane-2-carboxylate scaffolds: hexamers of oxetane cis-b-amino acids. Barker SF, Angus D*, Taillefumier C, Probert MR, Watkin DJ, Watterson MP, Claridge TDW*, Hungerford NL* & Fleet GWJ*, Tet Lett 42(25), 4247-4250 2001.
  6. Process for preparing clavam derivatives by using polypeptides having b-lactam synthetase activity. Barton B, McNaughton HJ*, Schofield CJ* & Thirkettle JE*, PCT Int. Appl. Patent: WO 0003581 (GB 98-15666, WO 99-GB2301), 31 Pages, 2000.
  7. How to guarantee optimal stability for most representative structures in the protein data bank. Bastolla U, Farwer J, Knapp EW & Vendruscolo M*, Proteins: Structure, Function & Genetics 44(2), 79-96 2001.
  8. b-Sultams - A novel class of serine protease inhibitors. Beardsell M, Hinchliffe PS, Wood JM, Wilmouth RC*, Schofield CJ* & Page MI, Chem Comm (5), 497-498 2001.
  9. Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors. Bentley J, Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA*, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury PJ, Johnson LN*, Noble MEM* & Newell DR, Clinical Cancer Res 6, 328 2000.
  10. MioC is an FMN-binding protein that is essential for Escherichia coli biotin synthase activity in vitro. Birch OM, Hewitson KS*, Fuhrmann M, Burgdorf K, Baldwin JE*, Roach PL* & Shaw NM, J Biol Chem 275(41), 32277-32280 2000.
  11. A historical perspective. How the structure of lysozyme was actually determined. Blake CCF*, Fenn RH, Johnson LN*, Koenig D, Mair G, North ACT, Phillips DC, Poljak R, Sarma VR & Vernon CA, In: Rossmann MG & Arnold E, ed. International Tables for Crystallography. 745-772, vol F. 2001.
  12. Structural investigations of pneumolysin/lipid complexes. Bonev B, Gilbert RJC* & Watts A*, Mol Membrane Biol 17(4), 229-235 2000.
  13. Structural analysis of the protein/lipid complexes associated with pore formation by the bacterial toxin pneumolysin. Bonev BB, Gilbert RJC*, Andrew PW, Byron O & Watts A*, J Biol Chem 276(8), 5714-5719 2001.
  14. Antiviral effect of N-butyldeoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins and Impairment of their association into E1-E2 heterodimers. Branza-Nichita N, Durantel D, Carrouƒe-Durantel S, Dwek RA* & Zitzmann N, J Virology 75, 4697-4712 2001.
  15. Clotting Factors VIII and IX. Brownlee GG* & Giangrande PLF, In: Buckel P, ed. Recombinant Protein Drugs (Milestones in drug therapy). Birkhauser Publishing Ltd, 67-88, 2001.
  16. A mechanism for initiating RNA-dependent RNA polymerization. Butcher SJ, Grimes JM, Makeyev EV, Bamford DH & Stuart DI*, Nature 410(6825), 235-240 2001.
  17. High sensitivity fluorescence anisotropy detection of protein folding events: application to a-lactalbumin. Canet D*, Doering K*, Dobson CM* & Dupont Y, Biophys J 80(4), 1996-2003 2001.
  18. Ultrastructural organization of amyloid fibrils by atomic force microscopy. Chamberlain AK*, MacPhee CE*, Zurdo J*, Morozova-Roche LA*, Hill HAO*, Dobson CM* & Davis JJ*, Biophys J 79(6), 3282-3293 2000.
  19. 2-amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. Chan JH, Hong JS, Hunter RN, Orr GF, Cowan JR, Sherman DB, Sparks SM, Reitter BE, Andrews CW, Hazen RJ, St Clair M, Boone LR, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver K, Ott RJ, Ren JS, Hopkins A, Stuart DI* & Stammers DK*, J Med Chem 44(12), 1866-1882 2001.
  20. Detection of two partially structured species in the folding process of the amyloidogenic protein b2-microglobulin. Chiti F*, Mangione P, Andreoli A, Giorgetti S, Stefani M, Dobson CM*, Bellotti V & Taddei N, J Mol Biol 307(1), 379-391 2001.
  21. Reduction of the amyloidogenicity of a protein by specific binding of ligands to the native conformation. Chiti F*, Taddei N, Stefani M, Dobson CM* & Ramponi G, Protein Science 10(4), 879-886 2001.
  22. Folding and binding. Emerging themes in protein folding and assembly (editorial overview). Clarke J & Dobson CM*, Current Opinion in Structural Biology 11(1), 67-69 2001.
  23. Nuclear magnetic resonance: a quantum technology for computation and spectroscopy. Cummins HK & Jones JA*, Contemp Physics 41(6), 383-399 2000.
  24. Resonance offset tailored composite pulses. Cummins HK & Jones JA*, J Mag Res 148(2), 338-342 2001.
  25. Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Davies TG, Tunnah P, Meijer L, Marko D, Eisenbrand G, Endicott JA* & Noble MEM*, Structure 9(5), 389-397 2001.
  26. Crystallization and functional analysis of a soluble deglycosylated form of the human costimulatory molecule B7-1. Davis SJ, Ikemizu S*, Collins AV, Fennelly JA, Harlos K*, Jones EY* & Stuart DI*, Acta Cryst D 57(4), 605-608 2001.
  27. Mutagenesis studies on the iron binding ligands of clavaminic acid synthase. Doan LX*, Hassan A*, Lipscomb SJ, Dhanda A*, Zhang ZH* & Schofield CJ*, Biochem & Biophys Res Commun 279(1), 240-244 2000.
  28. Experimental landscapes for protein folding and misfolding. Dobson CM*, Abs Papers Am Chem Soc 221, 2-COMP 2001.
  29. Fibrils. Dobson CM*, PCT Int. Appl. Patent: WO 0017328 (Patent Application Number: WO1999-GB03133), 51 Pages, 2000.
  30. The mechanism of amyloid formation and its links to human disease and biological evolution. Dobson CM*, In: Aggeli A, Boden N & Zhang S, ed. Self-Assem. Pept. Syst. Biol., Med. Eng., (Workshop 1999). Dordrecht, Netherlands: Kluwer Academic Publishers, 65-74, 2001.
  31. Mixed amyloid fibrils. Dobson CM*, PCT Int. Appl. Patent: PCT/GB01/05190 (UK 0028710), 2000.
  32. Protein folding and its links with human disease. Dobson CM*, In: From Protein Folding to New Enzymes. London: Portland Press, 1-26, Biochemical Society Symposium; vol 68. 2001.
  33. Protein folding, misfolding, and disease. Dobson CM*, Abs Papers Am Chem Soc 219, 64-PHYS 2000.
  34. The structural basis of protein folding and its links with human disease. Dobson CM*, Phil Trans R Soc Lond B 356(1406), 133-145 2001.
  35. Protein misfolding and disease - Preface to report of Royal Soc Discussion Meeting. Dobson CM*, Ellis RJ & Fersht AR, Phil Trans R Soc Lond B 356(1406), 129-131 2001.
  36. Aerosols in prebiotic chemistry. Dobson CM*, Ellison GB, Tuck AF & Vaida V, Abs Papers Am Chem Soc 222, 169-PHYS 2001.
  37. Atmospheric aerosols as prebiotic chemical reactors. Dobson CM*, Ellison GB, Tuck AF & Vaida V, Proc Nat Acad Sci USA 97(22), 11864-11868 2000.
  38. Structural insights into the diversity of the HLA-B53 motif and clade-specificity of HIV-specific cytotoxic T cells. Dorrell L, Wilcox BE, Jones EY*, Njai H, Sabally S, DeGleria K, Rostron T, Lepin E, Gillespie G, McMichael A, Whittle H & Rowland-Jones S, Eur J Immunol 31(6), 1747-1756 2001.
  39. Probing the penicillin sidechain selectivity of recombinant deacetoxycephalosporin C synthase. Dubus A, Lloyd MD*, Lee HJ*, Schofield CJ*, Baldwin JE* & Frere JM, Cellular & Mol Life Sci 58(5-6), 835-843 2001.
  40. Studies of isopenicillin N synthase enzymatic properties using a continuous spectrophotometric assay. Dubus A, Sami M*, Brown TJN, Schofield CJ*, Baldwin JE* & Frere JM, FEBS Lett 485(2-3), 142-146 2000.
  41. Study of the mechanism of antiviral action of iminosugar derivatives against bovine viraldiarrhea virus. Durantel D, Branza-Nichita N, Carrouƒe-Durantel S, Butters TD, Dwek RA* & Zitzmann N, J Virology 75, 8987-8998 2001.
  42. Geometric quantum computation. Ekert A, Ericsson M, Hayden P, Inamori H, Jones JA*, Oi DKL & Vedral V, J Modern Optics 47, 2501-2513 2000.
  43. C-elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Epstein ACR, Gleadle JM, McNeill LA*, Hewitson KS*, O'Rourke J, Mole DR, Mukherji M*, Metzen E, Wilson MI, Dhanda A*, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ* & Ratcliffe PJ, Cell 107(1), 43-54 2001.
  44. Amyloid fibrils from muscle myoglobin - Even an ordinary globular protein can assume a rogue guise if conditions are right. F€ndrich M*, Fletcher MA & Dobson CM*, Nature 410(6825), 165-166 2001.
  45. Observation of the noncovalent assembly and disassembly pathways of the chaperone complex MtGimC by mass spectrometry. F€ndrich M*, Tito MA*, Leroux MR, Rostom AA*, Hartl FU, Dobson CM* & Robinson CV*, Proc Nat Acad Sci USA 97(26), 14151-14155 2000.
  46. Mechanism of pH-dependent N-acetylgalactosamine binding by a functional mimic of the hepatocyte asialoglycoprotein receptor. Feinberg H, Torgersen D, Drickamer K* & Weis WI, J Biol Chem 275(45), 35176-35184 2000.
  47. Amantadine blocks channel activity of the transmembrane segment of the NB protein from influenza B. Fischer WB, Pitkeathly M* & Sansom MSP*, Eur Biophys J with Biophys Letts 30(6), 416-420 2001.
  48. Transmembrane peptide NB of influenza B: A simulation, structure, and conductance study. Fischer WB, Pitkeathly M*, Wallace BA, Forrest LR, Smith GR & Sansom MSP*, Biochemistry 39(41), 12708-12716 2000.
  49. Messenger RNAs that are not synthesised by RNA polymerase II can be 3' end cleaved and polyadenylated. Fodor E, Mikulāsovā A, Mingay LJ, Poon LLM & Brownlee GG*, EMBO Repts 1, 513-518 2000.
  50. Structure and enzymology of two bacterial diheme enzymes: cytochrome cd(1) nitrite reductase and cytochrome c peroxidase. Fülöp V*, Watmough NJ & Ferguson SJ*, Adv in Inorganic Chemistry 51, 163-204 2001.
  51. 95 GHz ESEEM of radical pairs: a source of radical separations and relative orientations. Fursman CE, Bittl R, Zech SG & Hore PJ*, Chem Phys Lett 342, 162-168 2001.
  52. Macromolecular cryo-crystallography. Garman EF, Turk D & Johnson LN*, In: Methods in Macromolecular Crystallography. IOS Press, 15-25, Nato Science Series; 2001.
  53. Structural basis of pore formation by cholesterol-binding toxins. Gilbert RJC*, Jimenez JL, Chen SX, Andrew PW & Saibil HR, Int J Medical Microbiology 290(4-5), 389-394 2000.
  54. Design, synthesis, and biological evaluation of O-6- alkylguanine and O-4-alkylpyrimidine cyclin-dependent kinase inhibitors. Griffin RJ, Arris CE, Calvert AH, Curtin NJ, Jewsbury P, Endicott JA*, Gibson AE, Boyle FT, Golding BT, Grant S, Johnson LN*, Noble MEM*, Newell DR & Lawrie A*, Abs Papers Am Chem Soc 219, 296-MEDI 2000.
  55. Cyclin dependent kinase inhibiting purine derivatives. Griffin RJ, Calvert AH, Curtin NJ, Newell DR, Golding BT, Endicott JA*, Noble MEM*, Boyle FT & Jewsbury PJ, PCT Int. Appl. Patent: WO9902162 (Application PCT/GB98/02025; 9714603.9; 9806743.2; US6303618; EP1017394), 1998.
  56. Cyclin dependent kinase inhibitors. Griffin RJ, Calvert AH, Curtin NJ, Newell DR, Golding BT, Endicott JA*, Noble MEM*, Boyle FT & Jewsbury PJ, PCT Int. Appl. Patent: WO9950251 (Application PCT/GB99/00830; 9806739.0; EP1066266), 1998.
  57. All in the genes? Groß M*, Chem in Brit 36(12), 28-30 2000.
  58. Balancing interests in autism study. Groß M*, Current Biology 11(16), R630-R630 2001.
  59. DNA architects. Groß M*, Chem in Brit 37(3), 21 2001.
  60. EnSnared. Groß M*, Chem in Brit 37(1), 15 2001.
  61. From e-ink to e-paper. Groß M*, Chem in Brit 37(7), 22-22 2001.
  62. The incredible nanoplotter. Groß M*, Chem in Brit 36(10), 25 2000.
  63. Insulin learns new tricks. Groß M*, Chem in Brit 37(2), 21-22 2001.
  64. Magnetic boost for structural studies. Groß M*, Current Biology 11(8), R286-R287 2001.
  65. The molecules of PAIN. Groß M*, Chem in Brit 37(6), 27-29 2001.
  66. New efforts develop therapeutic antibodies. Groß M*, Current Biology 11(14), R541-R542 2001.
  67. Protein crystals come of age. Groß M*, Chem in Brit 37(9), 28 2001.
  68. Protein design comes of age. Groß M*, Chem in Brit 37(5), 24-25 2001.
  69. Proteins that convert from a helix to b sheet: implications for folding and disease. Groß M*, Current Protein & Peptide Science 1(4), 339-347 2000.
  70. Putting cells together again. Groß M*, Current Biology 11(12), R452-R453 2001.
  71. Race quickens for the first human clone. Groß M*, Current Biology 11(7), R247 2001.
  72. Small is Great - Inside Science 142. Groß M*, New Scientist (14 July), 1-4 2001.
  73. Stem cells fuel bitter ethical divisions. Groß M*, Current Biology 11(15), R581-R582 2001.
  74. Sticking to stones. One person's lump of stone could be a bacterium's electron acceptor or energy source. Groß M*, Chemistry in Britain 37(8), 21 2001.
  75. Twists and turns in protein folding. Groß M*, Current Biology 11(3), R77-R78 2001.
  76. Analyzing protein functions in four dimensions. Hajdu J*, Neutze R, Sjogren T, Edman K, Szoke A, Wilmouth R* & Wilmot CM, Nature Struct Biol 7(11), 1006-1012 2000.
  77. Collectin structure: A review. Håkansson K & Reid KBM*, Protein Science 9, 1607-1617 2000.
  78. Contrasting fates for 6-a-methylpenicillin N upon oxidation by deacetoxycephalosporin C synthase (DAOCS) and deacetoxy/deacetylcephalosporin C synthase (DAOC/DACS). Hamilton CS, Yasuhara A, Baldwin JE*, Lloyd MD* & Rutledge PJ, Bioorganic & Medicinal Chem Lett 11(18), 2511-2514 2001.
  79. Fibrillin-1, a calcium binding protein of extracellular matrix. Handford PA*, Biochim Biophys Acta - Mol Cell Res 1498(2-3), 84-90 2000.
  80. Proteomics: A new concept for pharmaceutical research? Hebestreit HF & Dwek RA*, Eur Pharmaceutical Rev 2, 23-33 2001.
  81. Observation of the iron-sulphur cluster in Escherichia coli biotin synthase by nanoflow electrospray mass spectrometry. Hernandez H*, Hewitson KS*, Roach P*, Shaw NM, Baldwin JE* & Robinson CV*, Analytical Chemistry 73(17), 4154-4161 2001.
  82. Marfan syndrome caused by a mutation in FBN1 which gives rise to cryptic splicing and a 33 nucleotide insertion in the coding sequence. Hutchinson S, Wordsworth BP & Handford PA*, Hum Genet 109(4), 416-420 2001.
  83. Targeting of HIFa to the von Hippel-Lindau ubiquitylation complex by O-2-regulated prolyl hydroxylation. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M*, Schofield CJ*, Maxwell PH, Pugh CW & Ratcliffe PJ, Science 292(5516), 468-472 2001.
  84. Identification of a novel human islet amyloid polypeptide b-sheet domain and factors influencing fibrillogenesis. Jaikaran ETAS, Higham CE, Serpell LC*, Zurdo J*, Groß M*, Clark A & Fraser PE, J Mol Biol 308(3), 515-525 2001.
  85. Enhanced survival in Sandhoff disease mice receving a combination of substrate deprivation therapy and bone marrow transplantation. Jeyakumar M, Norflus F, Tifft CJ, Oylvaganam J, Cortina-Borja M, Butters TD, Proia RL, Perry VH, Dwek RA* & Platt FM, Blood 97, 327-329 2001.
  86. Conformational changes in response to phosphorylation. Johnson LN*, FASEB Journal 15(4), A27-A27 2001.
  87. The structural basis for substrate recognition and control by protein kinases. Johnson LN*, In: Schlichting I & Egner U, ed. Data Mining in Structural Biology. Berlin: Springer Verlag, Ernst Schering Research Workshop 34; 2001.
  88. Structural basis for control by phosphorylation. Johnson LN* & Lewis RJ, Chem Rev 101(8), 2209-2242 2001.
  89. Two epimerisations in the formation of oxetanes from L-rhamnose: towards oxetane-containing peptidomimetics. Johnson SW, Angus D*, Taillefumier C, Jones JH, Watkin DJ, Floyd E, Buchanan JG & Fleet GWJ*, Tetrahedron: Asymm 11(20), 4113-4125 2000.
  90. Blueprints for life or death. Jones EY*, Nature Immunology 2, 379-380 2001.
  91. The tumour necrosis factor receptor family: life or death choices. Jones EY*, Current Opinion in Structural Biology 10(6), 644-648 2000.
  92. NMR quantum computation. Jones JA*, Prog in NMR Spectr 38(4), 325-360 2001.
  93. NMR quantum computing. Jones JA*, In: Macchiavello C, Palma GM & Zeilinger A, ed. Quantum computation and quantum information theory. Singapore: World Scientific, 2001.
  94. Quantum computing and nuclear magnetic resonance. Jones JA*, PhysChemComm (11), 2001.
  95. Response of native and denatured hen lysozyme to high pressure studied by 15N/1H NMR spectroscopy. Kamatari YO*, Yamada H, Akasaka K, Jones JA*, Dobson CM* & Smith LJ*, Eur J Biochem 268(6), 1782-1793 2001.
  96. Studies on phytanoyl-CoA 2-hydroxylase and synthesis of phytanoyl-coenzyme A. Kershaw NJ*, Mukherji M*, MacKinnon CH*, Claridge TDW*, Odell B, Wierzbicki AS, Lloyd MD* & Schofield CJ*, Bioorganic & Medicinal Chem Lett 11(18), 2545-2548 2001.
  97. Structures and functions of mammalian collectins. Kishore U & Reid KBM*, In: Crocker PR, ed. Mammalian Carbohydrate Recognition Systems. Germany: Springer, 225-248, 2001.
  98. A recombinant homotrimer, composed of the alpha-helical neck region of human surfactant protein D and C1q B chain globular domain, is an inhibitor of the classical complement pathway. Kishore U, Strong P, Perdikoulis M & Reid KBM*, J Immunology 166, 559-565 2001.
  99. Studies of non-native conformational states in lysozyme. Klein-Seetharaman J, Grimshaw SB, Dobson CM* & Schwalbe H*, Biophys J 80(1), 2503 2001.
  100. Oxidative degradation of bilirubin produces vasoactive compounds. Kranc KR, Pyne GJ, Tao LM, Claridge TDW*, Harris DA, Cadoux-Hudson TAD, Turnbull JJ*, Schofield CJ* & Clark JF, Eur J Biochem 267(24), 7094-7101 2000.
  101. Probing subtle differences in the hydrogen exchange behavior of variants of the human a-lactalbumin molten globule using mass spectrometry. Last AM*, Schulman BA, Robinson CV* & Redfield C*, J Mol Biol 311(4), 909-919 2001.
  102. A hairpin loop structure in the 3' arm of the influenza A virus virion RNA promoter is required for endonuclease activit. Leahy MB, Dobbyn HC & Brownlee GG*, J Virology 75, 7042-7049 2001.
  103. Mutagenic analysis of the 5' arm of the influenza A virus virion RNA promoter defines the sequence requirements for endonuclease activity. Leahy MB, Pritlove DC, Poon LLM & Brownlee GG*, J Virology 75, 134-142 2001.
  104. Two-dimensional crystallisation of a membrane protein on a detergent-resistant lipid monolayer. Lebeau L, Lach F, Vƒnien-Bryan C*, Renault A, Dietrich J, Kuhlbrandt W, Thomas J, Palmgren M & Mioskowski C, J Mol Biol 308, 639-647 2001.
  105. Alteration of the co-substrate selectivity of deacetoxycephalosporin C synthase - The role of arginine 258. Lee H-J*, Lloyd MD*, Clifton IJ*, Harlos K*, Dubus A, Baldwin JE*, Frere JM & Schofield CJ*, J Biol Chem 276(21), 18290-18295 2001.
  106. Kinetic and crystallographic studies on deacetoxycephalosporin C synthase (DAOCS). Lee H-J*, Lloyd MD*, Harlos K*, Clifton IJ*, Baldwin JE* & Schofield CJ*, J Mol Biol 308(5), 937-948 2001.
  107. Correlation between viral resistance to zidovudine (AZT) and resistance at the reverse transcriptase level found for a panel of HIV-1 mutants. Lennerstrand J, Hertogs K, Stammers DK* & Larder BA, J Virology 75, 7202-7205 2001.
  108. Biochemical mechanism of HIV-1 reverse transcriptase resistance to stavudine (d4T). Lennerstrand J, Stammers DK* & Larder BA, Antimicrob Agents & Chemother 45, 2144-2146 2001.
  109. Molecular analysis of the epidermal growth factor-like short consensus repeat domain-mediated protein-protein interactions. Dissection of the CD55-CD97 complex. Lin H-H, Stacey M, Saxby C, Chaudhry Y, Evans D, Gordon S, McKnight AJ, Handford PA* & Lea S, J Biol Chem 276(26), 24160-24169 2001.
  110. A glimpse at changes to come - Meeting report [Commercial and Industrial Applications of Micro-Engineering and Nanotechnology, April 2000]. Liu L & Groß M*, Trends in Biotechnol 18(11), 440-441 2000.
  111. Carbopeptoids: peptides and diketopiperazines incorporating the anomeric centre of mannopyranose. Long DD*, Tennant-Eyles RJ, Estevez JC, Wormald MR, Dwek RA*, Smith MD & Fleet GWJ*, J Chem Soc Perkin Trans I (8), 807-813 2001.
  112. Hepatitis B virus MHBs antigen is selectively sensitive to glucosidase-mediated processong in the endoplasmic reticulum. Lu X, Lu Y, Geschwindt R, Dwek RA* & Block TM, DNA and Cell Biology 20, 647-656 2001.
  113. Formation of mixed fibrils demonstrates the generic nature and potential utility of amyloid nanostructures. MacPhee CE* & Dobson CM*, J Am Chem Soc 122(51), 12707-12713 2000.
  114. Lung surfactant proteins A and D protect mice against pulmonary hypersensitivity induced by Aspergillus fumigatus antigens and allergens. Madan T, Kishore U, Singh M, Strong P, Clark H, Hussain EM, Reid KBM* & Sarma PU, J Clin Invest 107, 467-475 2001.
  115. Protective role of lung surfactant D in a murine model of invasive pulmonary aspergillosis. Madan T, Kishore U, Singh M, Strong P, Hussain EM, Reid KBM* & Sarma PU, Infection & Immunity 69(4), 2728-2731 2001.
  116. Nonstandard peptide binding revealed by crystal structures of HLA-B*5101 complexed with HIV immunodominant epitopes. Maenaka K, Maenaka T, Tomiyama H, Takiguchi M, Stuart DI* & Jones EY*, J Immunology 165(6), 3260-3267 2000.
  117. Molecular recognition by Ig-like receptors , KIRS and FcgRs. Maenaka K, van der Merwe PA, Stuart DI*, Sondermann P & Jones EY*, In: Cooper MD, Tajai T & Ravetc JV, ed. Activating and Inhibitory Immunoglobulin-like Receptors. Springer, 45-54, 2001.
  118. The first epidermal growth factor-like domain of the low-density lipoprotein receptor contains a noncanonical calcium binding site. Malby S, Pickering R, Saha S, Smallridge RS*, Linse S & Downing AK*, Biochemistry 40(8), 2555-2563 2001.
  119. Sialoadhesin structure. May AP* & Jones EY*, In: Crocker P, ed. Mammalian Carbohydrate Recognition Systems. Springer-Verlag, 139-151, vol 33. 2001.
  120. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Mehta AS, Carrouee S, Conyers B, Jordon R, Butters T, Dwek RA* & Block TM, Hepatology 33, 1488-1495 2001.
  121. A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR: subunit organisation and binding to multivalent ligands. Mitchell DA, Fadden AJ & Drickamer K*, J Biol Chem 276, 28939-28945 2001.
  122. Structure-function analysis of phytanoyl-CoA 2-hydroxylase mutations causing Refsum's disease. Mukherji M*, Chien W, Kershaw NJ*, Clifton IJ*, Schofield CJ*, Wierzbicki AS & Lloyd MD*, Hum Mol Genet 10(18), 1971-1982 2001.
  123. 'Chemical co-substrate rescue' of phytanoyl-CoA 2-hydroxylase mutants causing Refsum's Disease. Mukherji M*, Kershaw NJ*, MacKinnon CH*, Clifton IJ*, Wierzbicki AS, Schofield CJ* & Lloyd MD*, Chem Comm (11), 972-973 2001.
  124. Identification of many crystal forms of Aspergillus nidulans dehydroquinate synthase. Nichols CE*, Ren J, Lamb H, Haldane F, Hawkins AR & Stammers DK*, Acta Cryst D 57(2), 306-309 2001.
  125. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. Oikonomakos NG, Schnier JB, Zographos SE, Skamnaki VT, Tsitsanou KE & Johnson LN*, J Biol Chem 275(44), 34566-34573 2000.
  126. Exploration of partially unfolded states of human a-lactalbumin by molecular dynamics simulation. Paci E*, Smith LJ*, Dobson CM* & Karplus M*, J Mol Biol 306(2), 329-347 2001.
  127. Expression and characterisation of the thrombospondin type I repeats of human properdin. Perdikoulis M, Kishore U & Reid KBM*, Biochim Biophys Acta 1548, 265-277 2001.
  128. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt-Ulms G, Mehlhorn IR, Legname G, Wormald MR, Rudd PM, Dwek RA*, Burton DR & Prusiner SB, Nature 412, 739-743 2001.
  129. Amyloid fibril formation by a helical cytochrome. Pertinhez TA*, Bouchard M*, Tomlinson EJ, Wain R*, Ferguson SJ*, Dobson CM* & Smith LJ*, FEBS Lett 495(3), 184-186 2001.
  130. NMR spectroscopic investigation of y torsion angle distribution in unfolded ubiquitin from analysis of 3J(Ca,Ca) coupling constants and cross correlated GcHNN,Ca,Ha relaxation rates. Peti W, Hennig M, Smith LJ* & Schwalbe H, J Am Chem Soc 122(48), 12017-12018 2000.
  131. Chemical shifts in denatured proteins: Resonance assignments for denatured ubiquitin and comparisons with other denatured proteins. Peti W, Smith LJ*, Redfield C* & Schwalbe H, J Biomol NMR 19(2), 153-165 2001.
  132. The hairpin structure of the 6F11F22F2 fragment from human fibronectin enhances gelatin binding. Pickford AR, Smith SP, Staunton D*, Boyd J* & Campbell ID*, EMBO J 20(7), 1519-1529 2001.
  133. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. Platt FM, Jeyakumar M, Andersson U, Priestman DA, Dwek RA* & Butters T, J Inherit Metabol Disease 24, 275-290 2001.
  134. Unfolded, yes, but random? Never! Plaxco KW* & Groß M*, Nature Struct Biol 8(8), 659-660 2001.
  135. Variable-temperature studies of order/disorder transitions in the thiourea pyridinium halide crystals by XRD and solid-state 2H NMR. Prout CK*, Heyes SJ, Dobson CM*, McDaid A, Maris T, Muller M & Seaman MJ, Chem Mat 12(12), 3561-3569 2000.
  136. A partially folded intermediate species of the b-sheet protein apo-pseudoazurin is trapped during proline-limited folding. Reader JS, Van Nuland NAJ*, Thompson GS, Ferguson SJ*, Dobson CM* & Radford SE, Protein Science 10(6), 1216-1224 2001.
  137. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. Ren J, Nichols C*, Bird L, Chamberlain P*, Weaver K, Short S, Stuart DI* & Stammers DK*, J Mol Biol 312(4), 795-805 2001.
  138. Structural basis for the resilience of Efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Ren JS, Milton J, Weaver KL, Short SA, Stuart DI* & Stammers DK*, Structure with Folding & Design 8(10), 1089-1094 2000.
  139. Mass spectrometry of proteins and peptides (Book review). Robinson CV*, J Am Soc Mass Spectrom 12(1), 126 2001.
  140. From individual proteins to whole cells - Editorial overview. Robinson CV* & Cowburn D, Current Opinion in Chemical Biology 5(5), 565-566 2001.
  141. A high-performance liquid chromatography based strategy for rapid, sensitive sequencing of N-linked oligosaccharide modifications to proteins in sodium dodecyl sulphate polyacrylamide electrophoresis gel bands. Rudd PM, Colominas C, Royle L, Murphy N, Hart E, Merry AM, Hebestreit HF & Dwek RA*, Proteomics 1, 285-294 2001.
  142. Glycosylation and the immune system. Rudd PM, Elliot T, Cresswell P, Wilson I & Dwek RA*, Science 291, 2370-2376 2001.
  143. Rapid, sensitive, HPLC-based sequencing strategies of N- and O-linked oligosaccharides attached to 5-20 micrograms of glycoproteins. Rudd PM, Mattu TS, Wormald MR, Harvey DJ & Dwek RA*, Pharmeuropa (April Special Issue), 103-118 2000.
  144. Holistic approaches to glycobiology: The genetic selection of mutant cells in a glycoconjungate biosynthetic pathway may provide insights into metabolic disease. Rudd PM, Opdenakker G & Dwek RA*, Nature Biotechnol 19, 531-532 2001.
  145. Prion glycoprotein: structure, dynamics, and roles for the sugars. Rudd PM, Wormald MR, Wing DR, Prusiner SB & Dwek RA*, Biochemistry 40, 3759-3766 2001.
  146. Solution structure of the LDL receptor EGF-AB pair: A paradigm for the assembly of tandem calcium binding EGF domains. Saha S, Boyd J*, Werner JM, Knott V, Handford PA*, Campbell ID* & Downing AK*, Structure 9(6), 451-456 2001.
  147. Hinges, swivels & switches: the role of prolines in signalling via transmembrane a-helices. Sansom MSP* & Weinstein H, Trends in Pharmacological Sci 21(11), 445-451 2000.
  148. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Saphire EO, Parren PWHI, Pantophlet R, wick MB, Morris GM, Rudd PM, Dwek RA*, Stanfield RL, Burton DR & Wilson I, Science 293, 1155-1159 2001.
  149. Preparation of oxopyrrolidinecarboxylates as serine protease inhibitors. Schofield CJ*, PCT Int. Appl. Patent: WO 200035871 (EP 1140821; GB 98-27499, WO 1999-GB4229), 45 Pages, 2000.
  150. A refined solution structure of hen lysozyme determined using residual dipolar coupling data. Schwalbe H*, Grimshaw SB*, Spencer A*, Buck M*, Boyd J*, Dobson CM*, Redfield C* & Smith LJ*, Protein Science 10(4), 677-688 2001.
  151. Binding of a peptide from a Streptococcus dysgalactiae MSCRAMM to the N-terminal F1 module pair of human fibronectin involves both modules. Schwarz-Linek U*, Plevin MJ, Pickford AR, Hook M, Campbell ID* & Potts JR*, FEBS Lett 497(2-3), 137-140 2001.
  152. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Shah PL, Hansell D, Lawson PR, Reid KBM* & Morgan C*, Thorax 55, 67-77 2000.
  153. Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with PhosphoCDK2. Song HW, Hanlon N*, Brown NR*, Noble MEM*, Johnson LN* & Barford D, Molecular Cell 7(3), 615-626 2001.
  154. Clarity through structures. Stubbe J & Johnson LN*, Current Opinion in Structural Biology 10(6), 709-710 2000.
  155. Carbohydrate receptor depletion as an antimicrobial strategy for prevention of urinary tract infection. Svensson M, Platt FM, Frendeus B, Butters T, Dwek RA* & Svanborg C, J Infectious Diseases 183, S70-S73 2001.
  156. The 1.8Å resolution structure of pig muscle 3-phosphoglycerate kinase with bound MgADP and 3-phosphoglycerate in open conformation: New insight into the role of the nucleotide in domain closure. Szilagyi AN, Ghosh M*, Garman E & Vas M, J Mol Biol 306, 499-511 2001.
  157. Folding and aggregation are selectively influenced by the conformational preferences of the a-helices of muscle acylphosphatase. Taddei N, Capanni C, Chiti F*, Stefani M, Dobson CM* & Ramponi G, J Biol Chem 276(40), 37149-37154 2001.
  158. Reconstitution of antigen presentation in HLA class I-negative cancer cells with peptide-b2m fusion molecules. Tafuro S, Meier UC, Dunbar PR, Jones EY*, Layton GT, Hunter MG, Bell JI & McMichael AJ, Eur J Immunol 31, 440-449 2001.
  159. Model calculations of magnetic field effects on the recombination reactions of radicals with anisotropic hyperfine interactions. Timmel CR, Cintolesi F, Brocklehurst B & Hore PJ*, Chem Phys Lett 334, 387-395 2001.
  160. A zero-field electron spin resonance spectrometer for the study of transient radical ion pairs. Timmel CR, Woodward JR, Hore PJ*, McLaughlin KA & Stass DV, Measurement Science & Technology 12, 635-643 2001.
  161. Improvements in or relating to microfluidic sample preparation and mass spectrometry. Tito MA* & Robinson CV*, PCT Int. Patent: WO 0050880 (GB 99-4038; Application WO 2000GB625), 41 Pages, 2000.
  162. Purification, crystallization and preliminary X-ray diffraction of anthocyanidin synthase from Arabidopsis thaliana. Turnbull JJ*, Prescott AG, Schofield CJ* & Wilmouth RC*, Acta Cryst D 57(3), 425-427 2001.
  163. Are anthocyanidins the immediate products of anthocyanidin synthase? Turnbull JJ*, Sobey WJ, Aplin RT*, Hassan A*, Firmin JL, Schofield CJ* & Prescott AG, Chem Comm (24), 2473-2474 2000.
  164. NMR analysis of structure and dynamics of the cytosolic tails of integrin alpha IIb b 3 in aqueous solution. Ulmer TS, Yaspan B, Ginsberg MH & Campbell ID*, Biochemistry 40(25), 7498-7508 2001.
  165. Matrix remodelling enzymes, the protease cascade and glycosylation. Van den Steen PE, Opdenakker G, Wormald MR, Dwek RA* & Rudd PM, Biochim Biophys Acta 1528, 61-73 2001.
  166. O-Linked glycosylation in focus. Van den Steen PE, Rudd PM, Wormald MR, Dwek RA* & Opdenakker G, Trends in Glycosci & Glycotechnol 63, 35-49 2000.
  167. Comparison of two optimization methods to derive energy parameters for protein folding: Perceptron and Z score. Vendruscolo M*, Mirny LA, Shakhnovich EI & Domany E, Proteins: Structure, Function & Genetics 41(2), 192-201 2000.
  168. Three key residues form a critical contact network in a protein folding transition state. Vendruscolo M*, Paci E*, Dobson CM* & Karplus M*, Nature 409(6820), 641-645 2001.
  169. Method of altering protein aggregation. Villegas V, Zurdo J*, Aviles FX, Dobson CM* & Serrano L, PCT Int. Appl. Patent: WO 2001027152 (Application No. WO 2000-GB3974; British patent application 9924484.0; International application PCT/GB00/03974), 87 Pages, 2001.
  170. Distinct pathways of Mannan-Binding Lectin (MBL)- and C1-complex autoactivation revealed by reconstitution of MBL with recombinant MBL-associated serine protease-2. Vorup-Jensen T, Petersen SV, Hansen AG, Poulsen K, Schwaeble W, Sim RB*, Reid KBM*, Davis SJ, Thiel S & Jensenius JC, J Immunology 165, 2093-2100 2000.
  171. Netherton's gene polymorphism and atopy in families with eczema and asthma. Walley AJ, Chavanas S, Moffat MF, Esnouf RM*, Ubhi B, Wong K, Lawrence R, Jones EY*, Harper JI, Hovnanian A & Cookson WOCM, Nature Genetics 29, 175-178 2001.
  172. Evidence for oxidation at C-3 of the flavonoid C-ring during anthocyanin biosynthesis. Welford RWD*, Turnbull JJ*, Claridge TDW*, Prescott AG & Schofield CJ*, Chem Comm (18), 1828-1829 2001.
  173. A G1127S change in calcium-binding epidermal growth factor-like domain 13 of human fibrillin-1 causes short range conformational effects. Whiteman P, Smallridge RS*, Knott V, Cordle JJ, Downing AK* & Handford PA*, J Biol Chem 276(20), 17156-17162 2001.
  174. Comparison of the denaturant-induced unfolding of the bovine and human a-lactalbumin molten globules. Wijesinha Bettoni R*, Dobson CM* & Redfield C*, J Mol Biol 312(1), 261-273 2001.
  175. Comparison of the structural and dynamical properties of holo and apo bovine a-lactalbumin by NMR Spectroscopy. Wijesinha Bettoni R*, Dobson CM* & Redfield C*, J Mol Biol 307(3), 885-898 2001.
  176. Chemical selection of elements by cells. Williams RJP*, Coord Chem Rev 216, 583-595 2001.
  177. The structures of organelles and reticula: Localised bioenergetics and metabolism. Williams RJP*, ChemBioChem 2(9), 637-641 2001.
  178. The biological chemistry of the elements - The inorganic chemistry of life. Williams RJP* & Frausto da Silva JJR, (2nd ed.) Oxford: Oxford University Press, 2001.
  179. The use of heavy element isotope fractionation in the study of the uptake of elements into cells. Williams RJP*, Onions K, Zhu X, Burgess BK, Canters GW, de Waal E, Matthews A, Salvato B & Weser U, J Inorg Biochem 86(1), 18-18 2001.
  180. X-ray snapshots of serine protease catalysis reveal a tetrahedral intermediate. Wilmouth RC*, Edman K, Neutze R, Wright PA*, Clifton IJ*, Schneider TR, Schofield CJ* & Hajdu J*, Nature Struct Biol 8(8), 689-694 2001.
  181. High-performance liquid chromatography analysis of ganglioside carbohydrates at the picomole level after ceramide glycanase digestion and fluorescent labelling with 2-aminobenzamide. Wing DR, Garner B, Hunnam V, Reinkensmeier G, Andersson U, Harvey DJ, Dwek RA*, Platt FM & Butters TD, Analytical Biochem 298, 207-217 2001.
  182. Radiofrequency magnetic field effects on electron-hole recombination. Woodward JR, Timmel CR, McLaughlin KA & Hore PJ*, Physical Rev Letts 87, 077602 2001.
  183. Kinetic and crystallographic analysis of complexes formed between elastase and peptides from b-casein. Wright PA*, Wilmouth RC*, Clifton IJ* & Schofield CJ*, Eur J Biochem 268(10), 2969-2974 2001.
  184. 'pH-jump' crystallographic analyses of g-lactam-porcine pancreatic elastase complexes. Wright PA*, Wilmouth RC*, Clifton IJ* & Schofield CJ*, Biochem J 351(2), 335-340 2000.
  185. A family of novel, acidic N-glycans in Bowes melanoma tissue plasminogen activator have L2/HNK-1-bearing antennae, many with sulfation of the fucosylated chitobiose core. Zamze S, Wing DR, Wormald MR, Hunter AP, Dwek RA* & Harvey DJ, Eur J Biochem 268, 4063-4078 2001.
  186. Preparation and characterization of purified amyloid fibrils. Zurdo J*, Guijarro JI* & Dobson CM*, J Am Chem Soc 123(33), 8141-8142 2001.
  187. Dependence on solution conditions of aggregation and amyloid formation by an SH3 domain. Zurdo J*, Guijarro JI*, Jimenez JL, Saibil HR & Dobson CM*, J Mol Biol 311(2), 325-340 2001.

Previous OCMS Members and staff publications lists:

1999/2000 - 1998/1999 - 1997/1998 - 1996/1997 - 1995/1996

Information updated 27th March 2002 by Lindsay Battle, OCMS Information Officer.

© Copyright 2009 University of Oxford